2.24
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché JAGX Giù?
Forum
Previsione
Frazionamento azionario
Jaguar Health Inc Borsa (JAGX) Ultime notizie
Is Jaguar Health Inc. a good long term investmentConsistent triple-digit returns - PrintWeekIndia
What drives Jaguar Health Inc. stock priceRapid capital growth - PrintWeekIndia
Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - Sentinel-Standard
What analysts say about Jaguar Health Inc. stockSkyrocketing investment returns - jammulinksnews.com
Jaguar Health Inc. Stock Analysis and ForecastAccelerated investment success - jammulinksnews.com
Form DEF 14A Jaguar Health, Inc. For: Aug 19 - StreetInsider
Published on: 2025-07-20 16:31:40 - Autocar Professional
Jaguar Health Announces Amendment to March 2020 Equity Purchase Agreement with Oasis Capital, LLC - FinancialContent
Jaguar Health Initiates Enrollment in Canalevia-CA1 Study for Chemotherapy-Induced Diarrhea in Dogs, Eyes EU Expansion. - AInvest
Clinical Trial Launches for First FDA-Approved Dog Diarrhea Treatment, Targeting $6B Pet Health Market - Stock Titan
Jaguar Health Eliminates Certain Royalty Obligations Reducing Future COGS for Mytesi and Crofelemer - ACCESS Newswire
Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS In - El Paso Times
Groundbreaking Deal: Peru Grants Access to Sacred Coca Plant for Mental Health Drug Research - Stock Titan
Investors Give Jaguar Health, Inc. (NASDAQ:JAGX) Shares A 36% Hiding - 富途牛牛
Jaguar Health Announces that Orphan Drug Designation Application Submitted to the FDA for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Has Been Accepted for Review - ACCESS Newswire
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Lohud
Jaguar Stock Price: Here’s current price trends, stock performance, key drivers, risks, forecast and more - The Economic Times
Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient - Worcester Telegram
Breakthrough Treatment Reduces Parenteral Nutrition by 27% in Orphan Disease PatientsNew Clinical Data - Stock Titan
Jaguar Health (JAGX) Announces $3.37M At-The-Market Stock Offering | JAGX SEC FilingForm 424B5 - Stock Titan
Jaguar Health (JAGX) Adopts Cryptocurrency as Treasury Asset | JAGX Stock News - GuruFocus
Jaguar Health considers cryptocurrency for treasury reserves - Investing.com
Jaguar Health (JAGX) Targets EU Approval for Canalevia in Dogs | - GuruFocus
Jaguar Health (JAGX) Targets EU Approval for Canalevia in Dogs | JAGX Stock News - GuruFocus
Jaguar Health seeks EU approval for dog diarrhea treatment - Investing.com
Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026 - The Columbus Dispatch
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):